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Abstract The increase of hepatic apolipoprotein B (apoB) 
mRNA editing during rat development was not affected by 
hypothyroidism. Furthermore, the addition of 3,3',5-triiodothyr- 
onine (T3) to cultured hepatocytes taken from fetal, neonatal and 
adult rats had no effect on apoB mRNA editing. In contrast, 
dexamethasone markedly stimulated apoB mRNA editing in 
hepatocytes taken from neonates. This effect was enhanced by 
the addition of insulin. For the fn-st time our data provide 
evidence that glucocorticoids together with insulin are important 
for the regulation of apoB mRNA editing during postnatal 
development, whereas thyroid hormones are not critical for this 
process. 
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and 30 of postnatal life to adult levels of 70% [7 10]. Addition 
of insulin for a longer period increased the apoB mRNA 
editing in primary rat hepatocytes in culture [8], just like sup- 
plementation of 3,3',5-triiodothyronine (T3) in hypothyroid 
rats [9]. However, the factors governing the increase in hepa- 
tocellular apoB production and apoB mRNA editing up to 
the weaning period are still unknown. 
In this study we show the changes in total apoB serum 
concentration observed during the perinatal development of 
rats. Furthermore, we analysed the effect of hypothyroidism 
on hepatic apoB mRNA editing during the suckling and 
weaning period and investigated the effect of dexamethasone, 
insulin and Ta on apoB mRNA editing and apoB-48 synthesis 
in cultured hepatocytes taken from fetal, neonatal and adult 
rats. 
1. Introduction 
Apolipoprotein B (apoB) is synthesized in the liver and 
small intestine of mammals as the structural component of 
triglyceride-rich very low density lipoproteins (VLDL) and 
chylomicrons. VLDL are the metabolic precursor of low den- 
sity lipoproteins (LDL), the main carrier of cholesterol in hu- 
mans. ApoB plays a crucial role in the secretion and catabo- 
lism of these lipoproteins. It exists in two forms, the full- 
length translation product apoB-100 and the shorter form 
apoB-48 which is identical to the amino-terminal 48% of 
apoB-100. ApoB-48 is the result of apoB mRNA editing, a 
posttranscriptional site-specific cytidine deamination that 
changes CAA for Gln-2153 in apoB-100 mRNA to a UAA 
stop codon [1]. In humans, apoB-48 is produced by the small 
intestine whereas the liver produces only apoB-100. In other 
mammals, like the rat and mouse, the liver is also able to 
synthesize apoB-48. Several components have been suggested 
to be required for the editing of apoB mRNA. The catalytic 
subunit of the postulated apoB editing complex, apobec-1, has 
been cloned [2] whereas the other protein factors are not yet 
identified. 
ApoB mRNA editing was demonstrated to undergo devel- 
opmental regulation in the intestine of all mammals including 
humans as well as in rat and mouse liver [3-6]. Generally, a 
low level of apoB mRNA editing of 10-20% was found in the 
neonatal rat liver. The editing rate increased between days 13 
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2. Materials and methods 
2.1. Animals 
Fetal (22nd day of gestation), neonatal (10th day of postnatal life) 
and adult (3 months old) Wistar rats of the strain Han-Wist were used 
in the experiments. Adult rats were housed under standardized con- 
ditions and fed a standard laboratory chow diet (Altromin) with water 
ad libitum. Neonatal rats were allowed free access to maternal milk 
until they were killed. Hypothyroidism of neonates was induced ac- 
cording to GaUo et al. [11] by addition of 0.1% 2-mercapto-l-methyl- 
imidazole (MMI) to the drinking water of the dams beginning on day 
22 of gestation. The serum concentrations of T3 and thyroxin (T4) 
were measured by means of a commercial radioimmunoassay (D no- 
test, Brahm's Diagnostica, Berlin). ApoB in the serum of rats was 
determined by means of rocket immunoelectrophoresis [12]. 
2.2. Primary hepatocyte culture 
Hepatocytes from adult and neonatal rats were isolated by a col- 
lagenase digestion method according to Zimmerman et al. [13]. He- 
patocytes from 10 day old rats were isolated by retrograde perfusion 
via the vena cava inferior. Hepatocytes from fetal rats were isolated 
using the method of Fry [14]. Generally, the vitality of the hepatocytes 
used for cultivation was higher than 85% when measured with the 
trypan blue exclusion technique. Cells were resuspended at a density 
of 1 X 106 cells/ml (fetal and neonatal rats) or 0.6 × 106 cells/ml (adult 
rats) in William's medium E supplemented with 10% fetal calf serum, 
26 mM NaHCO3 and 50 gg/ml gentamycin. 3 3 ml of the cell suspen- 
sion was plated on collagen coated 50 mm plastic culture dishes and 
maintained at 37°C in a water saturated atmosphere with 5% CO2. 
After 2 h, the plating medium and nonadherent cells were aspirated 
and replaced with 3 ml feeding medium per plate. The feeding me- 
dium consisted of William's medium E supplemented with 10% fetal 
calf serum, 26 mM NaHCO3 and 50 gg/ml gentamycin and, if indi- 
cated, with 100 nM dexamethasone, 50 nM T3 and 10 nM insulin, 
each alone or in combination with the others. Medium was replaced 
with fresh one daily. 
2.3. Measurement of [35 S]methionine incorporation i to secreted 
apoB-48 and apoB-lO0 
Following 72 h of culture the medium was replaced with 2 ml of 
fresh one and 40 laCi/ml [zSS]methionine was added. After 6 h of 
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incubation the medium was removed, centrifuged for removal of any 
tissue debris and set aside for analysis of apoB secretion. Cells were 
harvested and frozen in liquid nitrogen and stored at -80°C for RNA 
preparation. The analysis for measuring the incorporation of 
[35S]methionine to secreted apoB was done according to Plonn6 et 
al. [15]. After flotation of the medium at d= 1.21 g/ml the lipoprotein 
fraction was subjected to SDS-PAGE and the radioactivity of the 
excised apoB-100 and apoB-48 bands was measured by [3-counting. 
2.4. Primer extension analysis for determination fapoB mRNA editing 
The relative amounts of apoB-100 and apoB-48 mRNA were de- 
termined by primer extension analysis following reverse transcription 
and polymerase chain reaction (RT-PCR) amplification of total cel- 
lular RNA [3]. Total RNA from liver and from hepatocytes was 
prepared by acid guanidinium isothiocyanate-phenol-chloroform ex- 
traction [16]. RNA samples were treated with DNase to remove geno- 
mic DNA. RT-PCR was performed with Tth DNA polymerase (Pro- 
mega) and oligonucleotides ABT1 (nt 6614-6639) and ABT2 (nt 
6765-6740). This reaction resulted in products of 152 bp flanking 
the edited base [17]. ApoB eDNA was purified from oligonucleotides 
using QIAquick columns (Qiagen) and annealed to an antisense 
[y-z2P]ATP end labeled oligonucleotide (nt 6708-6674). Primer exten- 
sion was carried out with AMV reverse transcriptase (Promega) ac- 
cording to Driscoll et al. [18]. The reaction products indicative of 
apoB-100 and apoB-48 mRNA were separated on an 8% polyacryl- 
amide-urea gel, exposed to a GS-250 Imaging Screen B-I and analysed 
with the GS-250 Molecular Imager (Bio-Rad). 
Statistical differences were calculated by Student's t-test and con- 
sidered significant at P < 0.05. 
3. Results and discussion 
The changes in VLDL and LDL apoB serum concentration 
and hepatic apoB mRNA editing during the development of 
rats are shown in Fig. 1. During the suckling period the serum 
LDL apoB concentration was high and the apoB mRNA 
editing was low. During the weaning period, apoB mRNA 
editing increased to the adult value of 70%, which was reached 
on day 30 of life. This alteration ran parallel with the devel- 
opmental changes observed for VLDL apoB. The data reveal 
an inverse relationship between the LDL apoB concentration 
in the serum and the hepatic apoB mRNA editing. Obviously 
due to the low apoB mRNA editing in the suckling period, the 
liver mainly secretes apoB-100 containing lipoproteins result- 
ing in an increase in the serum concentration of LDL apoB. 
On the other hand, at the high rate of apoB mRNA editing 
observed after the weaning period the liver mainly produces 
apoB-48 containing lipoproteins (VLDL) which do not func- 
tion as precursors for LDL and which are eliminated much 
more quickly from the serum than lipoproteins containing 
apoB-100 [19-21]. This may lead to the lower LDL concen- 
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Fig. 1. Changes in VLDL (I) and LDL apoB (• )  serum concentra- 
tions (n = 7) and hepatic apoB mRNA editing (11) (n = 3) during rat 
development. For clear arrangement SD is not shown in the figure. 
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Fig. 2. Concentrations of T 3 and T4 in the serum of hypothyroid 
(• )  and control (11) animals during postnatal development (n = 3), 
values are given as means _+ SD. 
tration in the postweaning phase when compared with that 
measured in the suckling period. 
Different nutritional and hormonal conditions might be re- 
sponsible for these changes during the perinatal development 
of rats. The serum Ta concentration, for instance, is low in the 
fetal and suckling state and increases after the second week of 
life, peaking 4-5 weeks after birth [22]. Since T3 is known to 
stimulate apoB mRNA editing in the adult rat liver [23], we 
asked the question whether the increase in the T3 concentra- 
tion might be responsible for the observed increase in hepatic 
apoB mRNA editing. To test this hypothesis hepatic apoB 
mRNA editing was measured in hypothyroid animals. As 
shown in Fig. 2, MMI treatment effectively reduced the con- 
centration of T3 and T4 in the serum when compared with 
control animals. However, no differences in hepatic apoB 
mRNA editing were observed between the control and hy- 
pothyroid animals during the postnatal development. The 
proportion of edited apoB mRNA increased from about 
13% (2nd day of life) to about 22% (10th day of life), 47% 
(20th day of life) and 68% (30th day of life) in both groups. 
This result provides evidence that the thyroid hormones do 
not trigger the changes in apoB mRNA editing during the 
suckling and weaning period. 
To obtain greater insight into the regulation of hepatic 
apoB mRNA editing during development the effect of hor- 
mones on cultured hepatocytes was studied. The apoB 
mRNA editing measured in freshly isolated hepatocytes 
from fetal, neonatal and adult rats amounted to 50%, 28% 
and 85%, respectively (Figs. 3 and 4). These values of apoB 
mRNA editing were somewhat higher than those found for 
RNA isolated from liver tissues (compare Fig. 1). Without 
addition of hormones to the medium (see control in Fig. 4), 
the apoB mRNA editing decreased, independently of the in- 
itial value, to about 20% in the cells of all developmental 
stages after 72 h of cultivation. Ta did not show any effect 
on apoB mRNA editing in cultured hepatocytes from fetal, 
neonatal and adult rats. This finding, however, does not rule 
out an effect of T3 in vivo as reported by Davidson et al. [23] 
for adult rats, because thyroid hormones have been shown to 
modulate gene expression of growth hormone [24] known to 
affect the hepatic apoB mRNA editing [7]. 
When the cells were cultured in the presence of dexameth- 
asone, the apoB mRNA editing was significantly higher than 
in the corresponding controls without hormones (Figs. 3 and 
4). After the addition of dexamethasone alone to hepatocytes 
from adult rats apoB mRNA editing remained at a relatively 
high level of 50%. The combined addition of dexamethasone 
A. Lorentz et al./FEBS Letters 391 (1996) 57~50 
fetal neonatal adult 
59 
UAA 
(ApoB-48) 
CAA 
(ApoB-100) 
Primer 
1 2 3 4 1 2 3 4 1 2 3 4 
Fig. 3. Representative autoradiographs of primer extension analysis for determining the proportion of edited (UAA) and unedited (CAA) apoB 
mRNA. Total RNA was prepared from freshly isolated hepatocytes (1) and from cells cultured for 72 h without hormones (2) or with 100 nM 
dexamethasone (3)or with 100 nM dexamethasone plus 10 nM insulin plus 50 nM T3 (4). 
plus insulin, however, was still more efficient, leading to an 
apoB mRNA editing of about 71%, which was almost as high 
as the rate found in freshly isolated ceils. Interestingly, the 
combined effect of insulin and dexamethasone was actually 
more pronounced than expected on a simple additive level. 
In hepatocytes from neonates the apoB mRNA editing was 
increased to 58% after incubation in the presence of insulin 
plus Ta plus dexamethasone. This value was significantly high- 
er than the low value of 28% found in freshly isolated hepa- 
tocytes from the 10th day of life, indicating that apoB mRNA 
editing could be stimulated by hormone treatment. T3 and 
insulin alone had no significant effect but enhanced the stimu- 
lation of apoB mRNA editing by dexamethasone. The hor- 
monal stimulation of apoB mRNA editing in vitro might be 
relevant for the in vivo situation, since the insulin/glucagon 
ratio is low during the suckling period but high after weaning 
[22]. The same is true of the glucocorticoids. Their level is 
extremely low during the suckling period and increases trik- 
ingly after day 12-14 of life [25,26]. The missing effect of 
exogenous glucocorticoid administration to neonatal rats on 
hepatic apoB mRNA editing [4] indicates that a synergistic 
effect of different hormones on hepatic apoB mRNA editing 
might be important also in vivo. 
In comparison with the findings in hepatocytes from adult 
and neonatal rats, the effect of hormones on apoB mRNA 
editing was much less pronounced in those from fetal rats. 
Even the addition of insulin, dexamethasone and T3 in com- 
bination led to apoB mRNA editing of only about 35%, 
clearly less than the initial level of 50% determined in freshly 
isolated cells. 
In order to examine the editing process at the translational 
35 level, the incorporation of [ S]methionine into apoB-100 and 
apoB-48 secreted by the cultured hepatocytes was measured. 
Basically, the changes of apoB mRNA editing, found after 
hormone treatment in cultured hepatocytes from fetal, neona- 
tal and adult rats, were reflected at the protein level (data not 
shown). No significant differences were observed between the 
corresponding ratio of edited apoB mRNA to edited plus 
unedited apoB mRNA and the ratio of secreted apoB-48 
radioactivity to secreted apoB-48 plus apoB-100 radioactivity. 
Therefore, the editing is the major determinant of the form of 
apoB secreted not only in adult rats [7,8,27], but also during 
the developmental period. 
Our findings, that insulin alone had no significant effect on 
apoB mRNA editing but acted in a synergistic manner to- 
gether with dexamethasone, are noteworthy with regard to 
the results of others [8,28]. Pan and Koontz [28] analysed 
the effect of insulin on glucocorticoid receptor-mediated ran- 
scription using minimal artificial promoters. Insulin alone had 
virtually no effect on the expression of these promoters but it 
acted in a synergistic manner with glucocorticoids. 
Since an accumulation of apobec-1 mRNA is associated 
with an increase in apoB mRNA editing [29,30], one may be 
led to speculate that dexamethasone stimulates the expression 
of the apobec-1 gene via a glucocorticoid response lement 
(GRE) in the promoter and that insulin enhances this stimu- 
lation possibly through a component of the basic transcrip- 
tional apparatus. 
In summary, the data shown here demonstrate that T3 is 
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Fig. 4. ApoB mRNA editing of hepatocytes taken from fetal (n = 3), 
neonatal (n = 5) and adult (n = 5) rats before (A) and after cultiva- 
tion for 72 h (B). Cells were cultured without hormones (C) or with 
10 nM insulin (I), 50 nM Ta (T) or 100 nM dexamethasone (D), 
alone or in combination with each of the others. Values are given 
as means + SD. The star indicates ignificant differences at P < 0.05 
vs. the corresponding control (C). 
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not critical for increasing hepatic apoB mRNA editing during 
the postnatal development of the rat. Rather, glucocorticoids 
together with insulin seem to be important for the regulation 
of this process. The details of the mechanism of the stimula- 
tion of hepatic apoB mRNA editing, e.g. whether there exists 
a GRE-mediated control of apobec-1 gene expression, are still 
unknown and deserve further investigation. 
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